The North America RNA Based Therapeutic Market would witness market growth of 14.8% CAGR during the forecast period (2021-2027).
RNA polymerase synthesizes RNA from template DNA, with messenger RNA (mRNA) serving as a biomolecule that connects DNA expression and protein translation. Both coding and non-coding RNAs have drawn special attention in medicine due to their unique qualities (such as their typically single-stranded nature and their 2' OH group) as well as their propensity to adopt a variety of secondary/tertiary structures.
Antisense technology works by manufacturing a strand of RNA from a known gene sequence, whereas RNAi technology works by triggering the breakdown of specific mRNA molecules. These freshly formed RNA strands attach to mRNA, rendering it inactive. The ability of RNA-based therapies to silence genes is the key driver of market expansion.
North America is a lucrative hub for the RNA-based therapeutic market due to its robust and advanced healthcare infrastructure. North America is a region that comprises a significant number of patients that are being diagnosed with cancer. In addition, according to the data shared by the center for disease control and prevention, in 2019, there were 599,601 deaths that were caused by cancer of which 283,725 were among females while 315,876 were among males. The increasing prevalence of various chronic diseases among people across the region is also a crucial subject matter.
The US market dominated the North America RNA Based Therapeutic Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $3,959.7 million by 2027. The Canada market is estimated to witness a CAGR of 17.4% during (2021 - 2027). Additionally, The Mexico market would showcase a CAGR of 16.4% during (2021 - 2027).
Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global RNA Based Therapeutic Market is Estimated to reach $11.4 Billion by 2027, at a CAGR of 15.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- RNA Antisense
- RNA Interference (RNAi)
By Application
- Genetic disorders
- Auto immune disorders
By End User
- Research Institutes
- Hospitals & Clinics
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma, Inc.
- Alnylam Pharmaceuticals, Inc.
- Sanofi S.A. (Sanofi Genzyme)
- Biogen, Inc.
- Gradalis, Inc.
- Ionis Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc.
- Silence Therapeutics Plc
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America RNA Based Therapeutic Market, by Type
1.4.2 North America RNA Based Therapeutic Market, by Application
1.4.3 North America RNA Based Therapeutic Market, by End User
1.4.4 North America RNA Based Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
Chapter 4. North America RNA Based Therapeutic Market by Type
4.1 North America RNA Antisense Market by Country
4.2 North America RNA Interference (RNAi) Market by Country
Chapter 5. North America RNA Based Therapeutic Market by Application
5.1 North America Genetic disorders Market by Country
5.2 North America Auto immune disorders Market by Country
Chapter 6. North America RNA Based Therapeutic Market by End User
6.1 North America Research Institutes Market by Country
6.2 North America Hospitals & Clinics Market by Country
Chapter 7. North America RNA Based Therapeutic Market by Country
7.1 US RNA Based Therapeutic Market
7.1.1 US RNA Based Therapeutic Market by Type
7.1.2 US RNA Based Therapeutic Market by Application
7.1.3 US RNA Based Therapeutic Market by End User
7.2 Canada RNA Based Therapeutic Market
7.2.1 Canada RNA Based Therapeutic Market by Type
7.2.2 Canada RNA Based Therapeutic Market by Application
7.2.3 Canada RNA Based Therapeutic Market by End User
7.3 Mexico RNA Based Therapeutic Market
7.3.1 Mexico RNA Based Therapeutic Market by Type
7.3.2 Mexico RNA Based Therapeutic Market by Application
7.3.3 Mexico RNA Based Therapeutic Market by End User
7.4 Rest of North America RNA Based Therapeutic Market
7.4.1 Rest of North America RNA Based Therapeutic Market by Type
7.4.2 Rest of North America RNA Based Therapeutic Market by Application
7.4.3 Rest of North America RNA Based Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Approvals and Trials:
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments:
8.9.4.1 Partnerships, Collaborations, and Agreements:
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
TABLE 1 North America RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 2 North America RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– RNA Based Therapeutic Market
TABLE 4 Acquisition and Mergers– RNA Based Therapeutic Market
TABLE 5 Approvals and trials– RNA Based Therapeutic Market
TABLE 6 North America RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 7 North America RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 8 North America RNA Antisense Market by Country, 2017 - 2020, USD Million
TABLE 9 North America RNA Antisense Market by Country, 2021 - 2027, USD Million
TABLE 10 North America RNA Interference (RNAi) Market by Country, 2017 - 2020, USD Million
TABLE 11 North America RNA Interference (RNAi) Market by Country, 2021 - 2027, USD Million
TABLE 12 North America RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 13 North America RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 14 North America Genetic disorders Market by Country, 2017 - 2020, USD Million
TABLE 15 North America Genetic disorders Market by Country, 2021 - 2027, USD Million
TABLE 16 North America Auto immune disorders Market by Country, 2017 - 2020, USD Million
TABLE 17 North America Auto immune disorders Market by Country, 2021 - 2027, USD Million
TABLE 18 North America RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 19 North America RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 20 North America Research Institutes Market by Country, 2017 - 2020, USD Million
TABLE 21 North America Research Institutes Market by Country, 2021 - 2027, USD Million
TABLE 22 North America Hospitals & Clinics Market by Country, 2017 - 2020, USD Million
TABLE 23 North America Hospitals & Clinics Market by Country, 2021 - 2027, USD Million
TABLE 24 North America RNA Based Therapeutic Market by Country, 2017 - 2020, USD Million
TABLE 25 North America RNA Based Therapeutic Market by Country, 2021 - 2027, USD Million
TABLE 26 US RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 27 US RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 28 US RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 29 US RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 30 US RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 31 US RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 32 US RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 33 US RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 34 Canada RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 35 Canada RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 36 Canada RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 37 Canada RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 38 Canada RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 39 Canada RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 40 Canada RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 41 Canada RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 42 Mexico RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 43 Mexico RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 44 Mexico RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 45 Mexico RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 46 Mexico RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 47 Mexico RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 48 Mexico RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 49 Mexico RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 50 Rest of North America RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 51 Rest of North America RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 52 Rest of North America RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 53 Rest of North America RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 54 Rest of North America RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 55 Rest of North America RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 56 Rest of North America RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 57 Rest of North America RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 58 Key information – Arbutus Biopharma Corporation
TABLE 59 Key information – Arrowhead Pharmaceuticals, Inc.
TABLE 60 Key information – Benitec Biopharma, Inc.
TABLE 61 Key Information – Alnylam Pharmaceuticals, Inc.
TABLE 62 Key Information – Sanofi S.A.
TABLE 63 Key Information – Biogen, Inc.
TABLE 64 Key information – Gradalis, Inc.
TABLE 65 Key information – Ionis Pharmaceuticals, Inc.
TABLE 66 Key information – Sarepta Therapeutics, Inc.
TABLE 67 Key information – Silence Therapeutics plc
List of Figures
FIG 1 Methodology for the research
FIG 1 KBV Cardinal Matrix
FIG 2 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 3 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
FIG 4 Recent strategies and developments: Arbutus Biopharma Corporation
FIG 5 Recent strategies and developments: Sanofi S.A.